On the Forefront of COVID-19
Recognized leader in the COVID-19 field by governmental and non-governmental organizations as the reference assay development company in the vaccine field, from lead optimization through large scale advanced clinical, including:
Sofie Pattijn, Chief Technology Officer and Founder of ImmunXperts, has over 20 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development with a focus on functional assays for immunogenicity, immuno-oncology, and cell and gene therapy products. She has extensive hands-on lab experience and has managed and coached several in vitro teams over the last decade. From 2008 to 2013, Sofie was head of the in vitro immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics in Belgium for over 15 years.
Luc Gagnon, Vice President of Vaccine Sciences, leads scientific operations at Nexelis to support vaccines and biologics throughout the different phases of clinical trials. Luc brings over 20 years of experience in several biotech, CRO, and pharmaceutical companies to his role, including extensive expertise in ligand binding and microbiology/virology functional assay development, qualification, and validation.
Daniel Boster, Principal Scientist, brings more than 20+ years’ experience of early and late-stage large molecule bioanalytical science to Nexelis. Dan brings novel pharmacokinetic and immunogenicity assay development capability, with experienced troubleshooting techniques, to the regulated GXP environment. Dan’s work in the industry enabled him to gain firsthand experience with CROs: work collaboratively on assay development or validations, review regulated documents, and interpret sample analysis results.
Jennifer is the Director of Scientific Services at AIT Bioscience, a Nexelis company. In this role, she leads the LC/MS method development and validation team. She brings strengths in both organic chemistry and analytical method development to her position. At Stanford University, she received a Ph.D. in synthetic organic chemistry with Barry M. Trost. Positions in medicinal and process development chemistry at Eli Lilly and Company, Schering-Plough and ZDye, LLC utilized this skill set while also putting her at an interface with analytical teams and analytical method development. Her position at Phenomenex chromatography further honed her approaches to LC/MS method development while exposing her to a great range of methods across regulated and non-regulated pharmaceutical, food, environmental, cosmetic and petroleum industries. At AIT Bioscience, Jennifer continues to contribute to the scientific discussion through peer-reviewed journal contributions as well as presenting and volunteering for organizations such as AAPS.